What is the most appropriate insulin regimen for a patient with type 1 diabetes mellitus and chronic kidney disease?

Best Insulin for Type 1 Diabetes with CKD

For patients with type 1 diabetes and chronic kidney disease, use insulin analogs (both rapid-acting and long-acting) delivered via multiple daily injections or continuous subcutaneous insulin infusion, with strong consideration for automated insulin delivery systems to minimize hypoglycemia risk, which is substantially elevated in CKD. 1

Insulin Type Selection

Preferred: Insulin Analogs Over Human Insulin

The most recent ADA guidelines (2024) explicitly recommend insulin analogs over human insulins for type 1 diabetes patients to minimize hypoglycemia risk 1. This recommendation becomes even more critical in CKD, where:

• Hypoglycemia risk increases due to decreased insulin clearance and altered glucose metabolism
• Insulin requirements decrease as renal function declines, particularly with analogs
• Glucose variability increases, making predictable insulin action profiles essential

Specific Analog Recommendations

Long-acting basal insulins:

• Insulin degludec or U-300 glargine are preferred over U-100 glargine or NPH insulin 2, 3
• These newer-generation basal analogs confer lower hypoglycemia risk in type 1 diabetes 2, 3
• Research shows insulin glargine and detemir require 27-30% dose reduction at eGFR <60 mL/min compared to eGFR >90 mL/min, while human insulin shows less predictable dose-response relationships 4

Rapid-acting prandial insulins:

• Insulin lispro, aspart, or faster-acting aspart are recommended 2, 3, 1
• These reduce postprandial excursions and hypoglycemia compared to regular human insulin 2, 3
• Insulin lispro shows the most consistent dose reduction pattern with declining renal function (32.6% lower at eGFR <60 vs >90 mL/min) 4

Delivery System Priority

First Choice: Automated Insulin Delivery (AID)

Automated insulin delivery systems should be considered for all adults with type 1 diabetes 1, and this is particularly important in CKD because:

• AID systems adapt to increased glycemic variability that occurs with declining renal function 5
• They reduce nocturnal hypoglycemia without increasing A1C 6, 7
• The iDCL trial demonstrated superior time-in-range and reduced hypoglycemia compared to sensor-augmented pumps 6

Alternative: Multiple Daily Injections (MDI)

If AID is not feasible, use basal-bolus regimen with:

• 50% of total daily dose as basal insulin (once or twice daily)
• 50% as prandial insulin (divided before meals)
• Starting dose: 0.4-0.5 units/kg/day in stable patients 6, 3, 1

Critical CKD-Specific Adjustments

Dose Reduction Strategy

As renal function declines:

• Expect 25-30% reduction in insulin requirements at eGFR <60 mL/min 4
• Monitor more frequently for hypoglycemia as CKD progresses
• Reassess insulin regimen every 3-6 months 1

Hypoglycemia Prevention

This is the paramount concern in type 1 diabetes with CKD:

• Prescribe glucagon for all patients; non-reconstituted formulations preferred 1
• Use continuous glucose monitoring (CGM) early - this is now standard of care for type 1 diabetes and essential in CKD 1
• Avoid sliding scale insulin alone - never appropriate for type 1 diabetes 8

Common Pitfalls to Avoid

1. Using human insulin instead of analogs - This increases hypoglycemia risk, which is already elevated in CKD
2. Failing to reduce doses as eGFR declines - Insulin clearance decreases with kidney function, necessitating dose reductions
3. Not recognizing differential dose requirements - Different insulin analogs show varying dose-response relationships with declining renal function 4
4. Delaying CGM implementation - Early CGM use is recommended to manage increased glucose variability 1

Practical Implementation Algorithm

1. Initiate or continue insulin analogs (not human insulin)

   • Basal: degludec or U-300 glargine
   • Prandial: lispro, aspart, or faster-acting aspart

2. Choose delivery method:

   • First-line: AID system if patient capable
   • Alternative: MDI with basal-bolus regimen

3. Implement CGM immediately for all patients 1

4. Calculate initial dose:

   • Start at 0.4-0.5 units/kg/day if stable
   • Reduce by 20-30% if eGFR <60 mL/min
   • Split 50/50 between basal and prandial

5. Educate on carbohydrate counting and correction dosing 1

6. Prescribe glucagon and train caregivers 1

The evidence strongly supports insulin analogs over human insulin in this population, with the most recent 2024 ADA guidelines providing the highest-level recommendation (Grade A) 1. The addition of CKD to type 1 diabetes amplifies the importance of using predictable insulin formulations with lower hypoglycemia risk, making analog insulins the clear choice.